China’s CanSino recruits over 20,000 people for Covid vaccine trials

Published December 22, 2020
In this file photo, vials of a Covid-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China. — Reuters
In this file photo, vials of a Covid-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China. — Reuters

BEIJING: China’s CanSino Biologics Inc has recruited over 20,000 participants for late-stage human trials overseas for its coronavirus vaccine, a health official said on Monday.

The candidate, known as Ad5-nCoV or Convidecia, which CanSinoBIO is jointly developing with a research institute backed by the Chinese military, is among the five vaccines China has moved into Phase 3 clinical trials to test their efficacy.

“As for now, the number of recruited participants has exceeded 20,000 people, and the progress is relatively fast,” Zheng Zhongwei, an official at China’s National Health Commission, told a press conference.

Pakistan among states where participants are being listed

Phase 3 trials for CanSinoBIO’s candidate, which are planned to involve 40,000 participants in total, have begun enrolling participants in Pakistan, Russia, Mexico and Chile, the latest clinical trial registration data showed. The candidate also has trials lined up in Argentina and has secured a supply deal with Mexico.

The one-dose vaccine had been given to about 40,000-50,000 people in emergency use since it obtained approval for use in military personnel in June, CanSinoBIO Chief Executive Yu Xuefeng said in an industrial event on Nov 28.

A vaccine developed by Chinese Academy of Medical Sciences could start Phase 3 clinical trial soon, Zheng said on Monday, without specifying where it will be tested.

Published in Dawn, December 22nd, 2020

Opinion

Editorial

Kurram atrocity
Updated 22 Nov, 2024

Kurram atrocity

It would be a monumental mistake for the state to continue ignoring the violence in Kurram.
Persistent grip
22 Nov, 2024

Persistent grip

An audit of polio funds at federal and provincial levels is sorely needed, with obstacles hindering eradication efforts targeted.
Green transport
22 Nov, 2024

Green transport

THE government has taken a commendable step by announcing a New Energy Vehicle policy aiming to ensure that by 2030,...
Military option
Updated 21 Nov, 2024

Military option

While restoring peace is essential, addressing Balochistan’s socioeconomic deprivation is equally important.
HIV/AIDS disaster
21 Nov, 2024

HIV/AIDS disaster

A TORTUROUS sense of déjà vu is attached to the latest health fiasco at Multan’s Nishtar Hospital. The largest...
Dubious pardon
21 Nov, 2024

Dubious pardon

IT is disturbing how a crime as grave as custodial death has culminated in an out-of-court ‘settlement’. The...